| Clinical Significance: | Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness,
most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the
neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of
MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting
internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays
have similar sensitivities, but performing them together increases sensitivity of antibody detection by
approximately 5%. |
Home